AWH
Aspira Women's Health Inc. Common Stock
Delisted
AWH was delisted on the 17th of May, 2024.
About: Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its products include OvaSuite which is a portfolio of blood tests that applies proprietary algorithms incorporating patient features; OvaWatch intended for use in assessing the risk of ovarian cancer for women with adnexal masses; and Ova1Plus is a portfolio of blood tests, Ova1Plus is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.
Employees: 64
Financial journalist opinion
Neutral
Accesswire
1 day ago
Aspira Announces First Quarter 2025 Financial Results and Provides Business Update
AUSTIN, TX / ACCESS Newswire / May 19, 2025 / Aspira Women's Health Inc. ("Aspira") (OTCQB:AWHL), an AI enhanced bio-analytics based women's health company focused on delivering leading noninvasive gynecologic disease diagnostic and disease management tools, announced today its results of operations for the three-month period ended March 31, 2025. The Company also reported early progress under its new leadership team.
Neutral
Accesswire
1 week ago
Aspira Successfully Completes Application to the OTCQB
AUSTIN, TX / ACCESS Newswire / May 7, 2025 / Aspira Women's Health Inc. ("Aspira") (OTCQB:AWHL), an AI enhanced bio-analytics based women's health company focused on delivering the leading tools critical to gynecologic disease diagnostics and disease management, today announced it has successfully completed the process of transitioning to the OTCQB markets exchange. The Company begins trading on the OTCQB marketplace today, May 7, 2025.
Neutral
Accesswire
2 weeks ago
Aspira Reaches Another ARPA-H Milestone, Eligible to Receive Additional $1.5 Million in Second Quarter
Aspira Women's Health Submits the Third Milestone of ARPA-H $10 Million Award AUSTIN, TX / ACCESS Newswire / May 1, 2025 / Aspira Women's Health Inc. ("Aspira") (OTC PINK:AWHL), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the successful submission of its third development milestone of its Advanced Research Projects Agency for Health (ARPA-H) award. The third milestone focused heavily on additional analytical development steps.
Neutral
Accesswire
1 month ago
Aspira Women's Health Inc. to Begin Trading April 17th On OTC Under the Symbol "AWHL"
SHELTON, CT / ACCESS Newswire / April 17, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that at beginning of trading on April 17, 2025, the Company expects that its Common Stock will begin trading under its new symbol "AWHL" on markets operated by the OTC Markets Group, Inc. This symbol replaces the prior symbol "AWH" under which the Company previously traded. About Aspira Women's Health Inc. Aspira Women's Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases.
Neutral
Accesswire
1 month ago
Aspira Women's Health Inc. Announces Receipt of Delisting Notification from Nasdaq
SHELTON, CT / ACCESS Newswire / April 16, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that on April 15, 2025, the Company received written notice (the "Notice") from the Office of General Counsel of The Nasdaq Stock Market ("Nasdaq") indicating that the Nasdaq Hearings Panel has determined to delist the Company's shares from Nasdaq due to the Company's failure to meet Nasdaq's continued listing standards. As previously disclosed, the Company has not been compliant with the requirements under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2.5 million in stockholders' equity for continued listing on the Nasdaq Capital Market.
Neutral
Accesswire
1 month ago
Aspira Appoints Three New Directors, Executes $2.0 Million Equity Purchase Agreement
New Directors Bring Extensive Commercial Healthcare Relationships to Expand Business Development Opportunities. AUSTIN, TX / ACCESS Newswire / April 8, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of three new Directors to its Board of Directors.
Neutral
Accesswire
1 month ago
Aspira Receives $1.5 million Milestone Payment from the ARPA-H Sprint for Women's Health Award
The Company Successfully Reaches the Second Milestone of ARPA-H $10 Million Award AUSTIN, TX / ACCESS Newswire / March 31, 2025 / Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the successful completion of the second development milestone of its Advanced Research Projects Agency for Health (ARPA-H) award. As a result of satisfying the second development milestone, Aspira received a $1.5 million cash payment under the terms of the related $10 million agreement.
Neutral
Accesswire
1 month ago
Aspira Women's Health Reports Fourth Quarter and Full Year 2024 Financial Results
Record 2024 OvaSuite revenue of $9.2 million and volume of 24,305 units sold AUSTIN, TX / ACCESS Newswire / March 27, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (Nasdaq:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today reported its financial results for the fourth quarter and year ended December 31, 2024. Select financial results are as follows: Fourth Quarter 2024 and Recent Financial Highlights • Product revenue increased 9.5% to $2.3 million for the three months ended December 31, 2024, compared to $2.1 million for the same period in 2023.
Neutral
Accesswire
2 months ago
Aspira Women's Health Announces Closing of $1.37 Million Private Placement of Convertible Notes
AUSTIN, TX / ACCESS Newswire / March 11, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that it has entered into a securities purchase agreement dated March 6, 2025, pursuant to which the Company has sold and issued an aggregate principal amount of $1.37 million in the form of Senior Secured Convertible Promissory Notes due March 6, 2030 (the "Convertible Notes") in a private placement (the "Private Placement") with existing and new accredited investors. The Convertible Notes will be a senior, secured obligation of the Company and interest will accrue and be payable quarterly in kind at the applicable federal rate (currently 3.34%).
Neutral
Accesswire
3 months ago
Aspira Women's Health Submits Request for Withdrawal of Form S-1 Registration Statement
Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that it has filed a request for withdrawal with the Securities and Exchange Commission (the "SEC") of the Company's Registration Statement on Form S-1 (No. 333-284182), as amended, originally filed on January 8, 2025 (the "Registration Statement"), as the Company no longer intends to pursue a public offering under the Registration Statement at this time.
Charts implemented using Lightweight Charts™